PMID: 6403204Mar 1, 1983Paper

A profile of intravenous nitroglycerin use in cardiopulmonary bypass surgery

Canadian Anaesthetists' Society Journal
G E TownsendM C Bessette

Abstract

We studied the indications for use, time to onset of effect, approximate effective concentration and therapeutic success of commercially prepared intravenous nitroglycerin (NTG) in 50 patients undergoing cardiopulmonary bypass (CPB) surgery. Nitroglycerin was used to treat systemic or pulmonary hypertension, myocardial ischaemia and ventricular failure. Twenty-one patients had more than one indication for NTG use. Nineteen of 22 patients with pulmonary hypertension, 12 of 13 patients with ischaemic changes, and 13 of 15 patients with ventricular failure improved during intravenous NTG administration. Hypertension during CPB was ameliorated in only six of ten instances. The time to onset of effect ranged from 4.1 +/- 0.8 to 7.8 +/- 2.8 minutes and the mean approximate effective NTG concentration varied from 1.7 +/- 0.3 to 2.9 +/- 0.7 micrograms . kg-1.min-1 (doses only approximate due to our use of an infusion system which absorbs NTG). Complications from intravenous NTG administration were not seen. We conclude that this NTG preparation facilitates treatment of prebypass hypertension, pulmonary hypertension, myocardial ischaemia and ventricular failure but is less effective for the treatment of hypertension during CPB.

References

Aug 12, 1978·Lancet·P A CossumG W Boyd
Aug 3, 1978·The New England Journal of Medicine·W G GrouthamelR Shangraw
Oct 1, 1978·American Heart Journal·J E Cottrell, H Turndorf
Aug 11, 1977·The New England Journal of Medicine·J P DerridaP Chiche
May 1, 1978·Journal of Neurosurgery·J S ChestnutJ C Maroon
Jan 1, 1975·Circulation·J T FlahertyB Pitt
Jan 1, 1975·Circulation·J H McAnultyS H Rahimtoola
Jul 1, 1976·Anesthesiology·J A KaplanE L Jones
Nov 1, 1976·Anesthesiology·P Cleaton-Jones
Apr 1, 1974·The American Journal of Cardiology·K M KentS E Epstein
Oct 1, 1971·The Surgical Clinics of North America·J F Viljoen, M Y Gindi
Jul 1, 1981·Canadian Anaesthetists' Society Journal·L QuintinJ Burke
Jun 1, 1982·Anesthesia and Analgesia·D D Cote, M G Torchia
Nov 1, 1981·Anesthesia and Analgesia·J A Kaplan, P H Wells

❮ Previous
Next ❯

Citations

Jan 1, 1988·Annales Françaises D'anesthèsie Et De Rèanimation·J J LehotJ Villard
Jan 1, 1988·Acta Paediatrica Scandinavica. Supplement·F Serenius, A R Swailem
Jan 1, 1988·Acta Paediatrica Scandinavica. Supplement·F SereniusZ Sebai
May 1, 1993·The Journal of International Medical Research·K MikawaH Obara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.